RxDoctor Payments DataLook up a doctor →

Cameron Huxford, MD

Pulmonary Disease · Starkville, MSNPI 1972671626

Payments from drug & device makers

$155,410in general payments, 2019–2025

Across 549 payments — averaging $283.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$41K
  • Mallinckrodt Hospital Products Inc.$27K
  • Boehringer Ingelheim$19K
  • Mylan Specialty L.p.$18K
  • Sanofi$17K
  • Grifols USA, LLC$17K
  • plus $16K from 22 others

What the payments were for

  • Consulting fees$1,8481%
  • Speaking & faculty fees$138,72989%
  • Travel & lodging$7,0225%
  • Food & beverage$7,6925%
  • Education$750%
  • Entertainment$430%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$155,410 in reported general payments places this provider in the 95th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$50,427
Medicare patients
169
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$9,891
EliquisApixaban21$9,200
BreynaBudesonide/Formoterol Fumarate13$2,027
Potassium Chloride52$772
Colchicine20$567
Quetiapine Fumarate30$436
Pantoprazole Sodium63$424
Memantine Hcl19$397
Albuterol Sulfate HfaAlbuterol Sulfate16$349
Levothyroxine Sodium73$333
Gabapentin25$295
Furosemide78$248
ClopidogrelClopidogrel Bisulfate59$223
Allopurinol41$220
Famotidine59$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$40,844$9,89116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Starkville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →